Comparing the current results to its competitors, Iteos Therapeutics Inc reported Revenue decrease in the 2 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.4 %, recorded in the same quarter.
Iteos Therapeutics Inc , slower than the average decrease reported by the company's competitors of -22.02 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -22.02 %
December 13, 2024
Incyclix Bio has recently announced promising interim results from its ongoing Phase 1/2 clinical trial assessing the efficacy of INX-315 in patients with CDK4/6 inhibitor-resistant ER+/HER2- breast cancer or CCNE1-amplified solid tumors. The preliminary findings revealed that INX-315 was safe and well-tolerated in monotherapy dose escalation. This development underscores Incyclix Bio s commitment to advancing therapeutics for cancer types that exhibit resistance to conventional treatment options.CDK4/6 inhibitors are a class of drugs that have significantly contributed to the treatment arsenal against certain types of breast cancer. However, resistance over time remains a formidable challenge, necessitating...
July 8, 2024
iTeos Therapeutics, a clinical-stage biopharmaceutical company dedicated to revolutionizing immuno-oncology treatment options, has recently made significant progress in its pursuit of developing novel therapeutics. The company has reported the initiation of the GALAXIES Lung-301 Phase 3 study, evaluating belrestotug and dostarlimab versus placebo and pembrolizumab in patients with advanced PD-L1 high non-small cell lung cancer (NSCLC). Additionally, iTeos presented encouraging preclinical data on the potent small molecule inhibitor, EOS-984, targeting the equilibrative nucleoside transporter 1 (ENT1) at the American Association for Cancer Research (AACR) Annual Meeting.1. GALAXIES Lung-301 Phase 3 Study:iTeo...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.
Sources:
Iteos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Iteos Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
